Table 5.
Crude and adjusted OR and 95% CI of the association between ICS use and incident glaucoma between 2003 and 2006
| ICS | Crude OR | 95% CI | Adjusted OR | 95% CI |
|---|---|---|---|---|
| Ever use in the last year | ||||
| No use | Reference | – | Reference | – |
| Use | 0.98 | (0.72–1.34) | 0.94 | (0.64–1.38) |
| Last use prior to index date (days) | ||||
| No use | Reference | – | Reference | – |
| 18 days | 1.18 | (0.77–1.81) | 1.07 | (0.62–1.82) |
| 19–38 days | 0.85 | (0.53–1.35) | 0.74 | (0.41–1.34) |
| 39–100 days | 1.82 | (1.19–2.76) | 1.82 | (1.08–3.05) |
| 101–365 days | 0.63 | (0.38–1.04) | 0.55 | (0.31–0.99) |
| Duration of use (days) | ||||
| No use | Reference | – | Reference | – |
| 1–120 | 0.94 | (0.6–1.47) | 0.83 | (0.49–1.43) |
| 121–230 | 0.99 | (0.61–1.6) | 0.78 | (0.43–1.4) |
| 231–380 | 1.10 | (0.71–1.68) | 0.92 | (0.53–1.58) |
| ≥381 | 1.27 | (0.83–1.94) | 1.15 | (0.68–1.95) |
| Number of prescriptions | ||||
| None | Reference | – | Reference | – |
| 1–3 | 0.91 | (0.59–1.39) | 0.85 | (0.51–1.41) |
| 4–5 | 1.29 | (0.81–2.07) | 1.17 | (0.67–2.04) |
| 6–8 | 1.12 | (0.72–1.75) | 0.86 | (0.49–1.52) |
| ≥9 | 1.07 | (0.69–1.66) | 0.86 | (0.49–1.49) |
Notes: Population includes patients with COPD in the GPRD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and number of years in the cohort prior to the event of interest. Models Adjusted for FSC, asthma, long-acting beta agonists, short-acting bronchodilators, oral corticosteroids, BMI, smoking status, statin use, depression, diabetes, oxygen use, nebulizer use, and count of antibiotic prescriptions.
Abbreviations: BMI, body mass index; CI, confidence interval; FSC, fluticasene propionate/salmeterol fixed-close combination; GPRD, General Practice Research Database OR, odds ratio.